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Studies on the inflammatory burden in recent-onset psoriatic arthritis (PsA) patients 
without conventional cardiovascular risk factors (CVRFs) are not available. This prelimi-
nary study focuses on cardiovascular risk in cutaneous psoriasis (CPs) and recent-onset 
PsA patients. Blood biochemistry (glucose, cholesterol, uric acid, lipid profile and apo-
lipoprotein B) was analyzed using standard kits. Proatherogenic inflammation markers, 
C-reactive protein (CRP) and interleukin-6 (IL-6), and endothelial activators monocyte 
chemoattractant protein-1 (MCP-1) and soluble intercellular adhesion molecule-1 
(sICAM-1), were determined by enzyme-linked immunosorbent assay. Ultrasound 
images allowed measuring carotid intima–media thickness (cIMT). Our study first 
shows an increase in cIMT, and in serum levels of sICAM-1 and CRP in recent-onset 
PsA patients not presenting conventional CVRFs over the non-medicated time-period, 
from disease diagnosis to the beginning of pharmacological treatment, compared with 
healthy subjects. The outcome highlights the importance of monitoring serum level of 
sICAM1, CRP, and cIMT, and the value of primary prevention in psoriatic patients even 
with no history of cardiovascular events.
Keywords: atherogenesis, atherosclerosis, chronic inflammation, c-reactive protein, psoriatic arthritis, carotid 
intima–media thickness, il-6, soluble intercellular adhesion molecule-1
inTrODUcTiOn
Psoriasis (Ps) and psoriatic arthritis (PsA) belong to the family of immune mediated inflammatory 
diseases (IMID) predominantly affecting skin and joints (1). Epidemiological studies show a peak 
incidence of Ps between the second and third decades of life (2) and a global prevalence around 
2–3% regardless of sex (3). Approximately 7–42% of Ps patients develop inflammatory arthropathy 
as either mono or asymmetrical oligoarthritis (4).
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The only blood biomarkers currently recommended in pre-
dicting cardiovascular risk are lipid-related indicators, however, 
lipid profile alone reflect only relative cardiovascular risk, as 
more than half of all cardiovascular events can occur in individu-
als with concentrations below the mean of total cholesterol (5).
The inflammatory background of atherosclerosis is undeniable 
(6). Epidemiological studies show that PsA is a high-risk factor 
for cardiovascular disease (CVD) (7–10) likely related to chronic 
inflammation leading to endothelial dysfunction (11) and plaque 
formation (12). Accelerated atherosclerosis has been linked to 
cutaneous psoriasis (CPs) according to its severity, even in the 
absence of joint symptoms (13).
Circulating markers of systemic inflammation could reli-
ably anticipate cardiovascular morbidity and mortality (14). 
Soluble intercellular adhesion molecule-1 (sICAM-1), matrix 
metalloproteinase-3, N-terminal pro-B-type natriuretic peptide, 
interleukin-6 (IL-6), soluble CD40 ligand, and insulin-like 
growth factor binding protein-2, as well as age and diabetes mel-
litus, were found strongly associated with death and myocardial 
infarction (15).
On the other hand, similarities in immunopathogenic pro-
file (Th1/Th17) between atherosclerosis (6, 16) and systemic 
inflammatory diseases like PsA and CPs have become an 
increasing topic of research. Therefore, systemic inflammatory 
markers such as C-reactive protein (CRP), interleukin-6 (IL-
6) and soluble intercellular adhesion molecule-1 (sICAM-1) 
in combination with carotid intima–media thickness (cIMT) 
might be useful for cardiovascular risk (CVR) estimation (17, 
18). Moreover, previous studies concluded that CRP, IL-6, and 
sICAM-1 showed more consistent results and independent pre-
dictive value than other inflammatory markers of atherogenesis 
(17). The contribution of IL-6 to the pivotal role of inflamma-
tion shared by psoriasis and atherosclerosis is crucial (19). 
Consistent with this point of view, CRP has been implicated 
in the pathogenesis of atherosclerosis (20) and appears to be 
not only a consistent predictor of cardiovascular events but an 
independent risk factor for myocardial infarction, stroke, and 
peripheral vascular disease as well (21). Of note, robust cor-
relation reported for CRP serum levels with the Psoriasis Area 
and Severity Index (PASI) suggests that PASI is a measure of 
increased systemic inflammation rather than local skin inflam-
mation (22). The isolated CRP level may be used in context with 
other CVR surrogate markers and clinical information to serve 
as a diagnostic tool (23).
The hepatic release of CRP increases the inflammatory burden 
in blood favoring endothelial wall injury (20). Whether the num-
ber and distribution of CRP receptors differ in PsA from those 
found in the general population requires more studies.
This study reports the noninvasive characterization of the 
immune-inflammatory profile associated with cardiovascular 
risk (CVR) in psoriatic patients not expressing the typical CVR 
factors. Inflammation was evaluated measuring endothelial and 
systemic markers, immunophenotype activation, inflammatory 
oxidation, and prothrombotic factors.
A rise in the blood level of sICAM-1 may reveal early proathero-
genic alterations in the artery wall. The blood level of sICAM-1 
has been related to the chronic and progressive inflammation 
underlying plaque formation in the coronary and carotid arteries 
appearing even decades before clinical CVD (24).
Among other markers, the monocyte chemoattractant 
protein-1 (MCP-1) has been implicated in atherosclerosis and 
coronary/peripheral arterial disease (24). It is a member of the 
C-C chemokine family produced by monocytes/macrophages, 
smooth muscle cells, endothelial cells (25–28), and adipocyte, 
and plays a key role in cardiovascular diseases. It is recognized by 
CCR-2 receptors on monocytes and serves as a chemotactic agent 
to recruit monocytes into the vascular wall (28). Pathogenesis and 
activity of psoriasis vulgaris may involve changes in MCP-1 blood 
levels (29). The level of systemic MCP-1 might provide informa-
tion of local inflammation and has been proposed as a marker to 
assess disease severity in psoriatic patients (30).
To our knowledge, the relationship between cIMT, proin-
flammatory, and endothelial activation markers has not been 
thoroughly studied in recently diagnosed non-medicated PsA 
(29). This cross-sectional study compares the degree of athero-
genesis based on subclinical parameters as cIMT, the presence 
of atherosclerosis plaque, and early inflammatory markers 
(CRP, IL-6, MCP1, and sICAM-1) in recent-onset PsA patients, 
low-intermediate CPs patients (control group accounting for 
inflammatory setting), and healthy subjects. Patients present-
ing conventional CVR factors or confounding comorbidities 
(diabetes) were excluded to avoid biased interpretation of data. 
Current evidence suggests that the inflammatory pathways 
involved in atherosclerosis modify peripheral blood levels of mol-
ecules derived from oxidative stress and vascular inflammation 
markers like CRP (31, 32), IL-6, membrane and soluble ICAM1 
(ICAM1s) and MCP1 (30, 31). An important early step in the pro-
cess of atherosclerosis is the adhesion of monocytes to activated 
endothelial cells, in which various adhesion molecules including 
ICAM1 are involved. TNFα, IL-1, IFNγ, and other cytokines 
induce endothelial ICAM1 expression (31, 33). Th1 secreting 
inflammatory cytokines also contribute to the pathogenesis of 
atherogenesis and psoriasis (34, 35).
sUBJecTs anD MeThODs
study Design
Men and women between 25 and 75  years old attending the 
Hospital JM Ramos Mejía of Buenos Aires (HJMRM), Argentina, 
were recruited between April 2012 and December 2016. 
Following the selection process described below, 32 patients 
entered the study. Three groups were matched for age and body 
mass index (BMI): C (9 control healthy patients), CPs (9 low-
intermediate CPs patients to account for psoriasis inflammation), 
and PsA (14 patients with recent PsA onset following low- 
intermediate CPs).
All participants signed written consent to join the study and 
completed a validated questionnaire. It conveyed anthropometric 
data, medical history, smoking status, dietary habits, alcohol 
consumption, exercise practice, and current medication for 
hypertension or diabetes.
The respective Institutional Ethics Committees of the Faculty 
of Medicine of the University of Buenos Aires (Comité de Bioética 
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de la Facultad de Medicina de la Universidad de Buenos Aires) 
and of the Hospital JM Ramos Mejía (Comité de ética en investi-
gación del Hospital José María Ramos Mejía del Gobierno de la 
Ciudad de Buenos Aires, Argentina, registered at The Office for 
Human Research Protections, NIH, USA Code FWA 00001767) 
approved the study protocol.
subjects’ recruitment
Consecutive patients either satisfying the CASPAR classifica-
tion criteria for psoriatic arthritis (36) or discarded from PsA 
diagnosis after rheumatologic evaluation were recruited at the 
Rheumatology Department and at the Dermatology Department 
and included in the PsA or the CPs group, respectively.
Before entering the study, both PsA and CPs cohorts were 
screened out for subclinical cardiovascular risk factors (CVRFs) 
or any ongoing inflammatory process. All participants underwent 
clinical and nutritional evaluation and a selection process based 
on the criteria shown below.
clinical exclusion criteria
Any of the followings were determinant for exclusion from the 
study:
•	 Concurrent disease.
 ◦ Chronic inflammatory or non-inflammatory illness, renal 
or hepatic failure.
 ◦ Metabolic syndrome (MetS) (37). Coexistence of at least 3 of 
the following: abdominal obesity, hyperglycemia, hyperin-
sulinemia or diabetes, hypertriglyceridemia or low HDL-C, 
and hypertension (38).
•	 Smoking history or current smoking (≥1 daily pack within 
2 years before the study).
•	 Body mass index (BMI) <18.5 kg/m2 (underweight) or ≥30 kg/
m2 (obesity).
•	 Alcohol consumption: more than 100 mL wine/day every day 
or equivalent.
•	 Treatment with anti-inflammatory drugs (NSAID), predni-
sone, TNF-blockers, disease-modifying antirheumatic drugs 
(DMARDs), hypocholesterolemic, or antidiabetic drugs.
•	 Cardiovascular history. Prior myocardial infarction, ictus, 
preexistent peripheral vascular disease, or so on.
•	 Hypertension. Diagnosed hypertension: SBP  ≥  130  mmHg/
DBP ≥ 85 mmHg (38).
•	 Pregnancy.
Biochemical exclusion criteria
Lipoproteins and other conventional CVR markers were meas-
ured, and associated CVR indices were calculated.
•	 Hyperglycemia either fasting > 140 mg/dL or postprandial >  
200 mg/dL.
•	 Dislipemia (cholesterolemia  >  240  mg/mL, HDL-C  <  35   
mg/100mL, LDL-C > 160 mg/dL, or TG ≥ 170 mg/dL).
•	 Triglyceridemia < 150 mg/dL
•	 Apolipoprotein B (ApoB) ≥ 130 mg/dL. Serum concentration 
of apolipoprotein was measured using nephelometry.
Of note, cutoff levels were set at ≥35 mg/dL for HDL cholesterol 
and >100 mg/dL for ApoB to avoid a substantial reduction in the 
number of patients in the study. Castelli index (total cholesterol/
cholesterol HDLc) and the ApoB100/ApoA1 ratio were calculated 
to get the picture of the CVR relative to plasma atherogenicity. A 
Castelli index < 5 for men or <4.5 for women is related to a low 
CVR while higher values suggest a high CVR (39).
Determinations
Psoriasis Activity and Severity
Disease activity score (DAS28) and Psoriasis Area and Severity 
Index (PASI) were calculated for PsA. For CPs, disease activity 
index was restricted to PASI (low: 0–20; mild: 21–50; severe: 51–72). 
Values of DAS28 <  3.2 indicated low activity disease, whereas 
values >5.1 were consistent with high disease activity (40, 41). The 
activity score of DAS28, which assesses exclusively joint involve-
ment, was used to evaluate the severity of PsA (41, 42). Current 
psoriasis activity was determined by the Psoriasis Area and Severity 
Index (PASI) which combines severity (erythema, induration, and 
desquamation) and extension of lesions (% of affected area) (43).
Subclinical Marker: cIMT
Ultrasound images of cIMT were recorded within the month of 
PsA diagnosis. cIMT was defined as the distance (cm) between the 
inner echogenic line representing the intima–blood interface and 
the outer echogenic line representing the adventitia-media junc-
tion. It was measured at the right and left branches, and the highest 
value was considered. The distance from the posterior wall of the 
common carotid arteries was measured at 1 cm from the carotid 
bulb (bifurcation into external and internal branches). Carotid 
plaques were also measured (Philips EnVisor C HD Ultrasound 
Transducer). Values of IMT >0.85  mm indicate atherosclerosis 
and >1.50 mm are consistent with atheromatous plaques.
Non-Conventional and Conventional Cardiovascular 
Risk Factors
Nonconventional CVRF include proinflammatory cytokines, 
endothelial activation markers, and CRP. General unspecific 
inflammatory markers were measured using Commercial 
enzyme-linked immunosorbent assay (ELISA) kits, according 
to the manufacturer’s technical specifications. Following 12 h 
overnight fasting, blood samples were collected and analyzed for 
glucose, cholesterol, uric acid, lipid profile, and apolipoprotein 
B. Routine determinations were performed using standard kits 
(Roche Products).
High-Sensitivity C-Reactive Protein (hs-CRP)
The hs-CRP ELISA from GenWay Biotech, Inc. (San Diego, CA, 
USA) was used to measure total CRP serum levels. Detection 
limit was 0.0002 mg/mL. Samples with high levels were diluted 
and re-assayed. In 2013, the American Heart Association and 
US Centers for Disease Control and Prevention (1913) defined 
risk groups according to hs-CRP values (mg/L): normal <  0.8, 
low risk <  1.00, average risk: 1.00–3.00, and high-risk >  3.00. 
Measuring hs-CRP is only recommended when Framingham 
clinical score is >5 and <10 years.
Interleukin 6 (IL-6)
An in vitro ELISA for the quantitative measurement of human 
IL-6 in serum was performed using the human IL-6 ELISA kit 
TaBle 1 | Demographical data and blood lipid profile.
Factor control (n = 9) cPs (n = 9) Psa (n = 14)
Age 45.3 ± 16.4 50.3 ± 7.5 49.4 ± 18.5
Male, n (%) 8 (88) 6 (66) 11(78)
Caucasian, n (%) 9 (100) 9 (100) 14 (100)
BMI (kg/m2) 25.9 ± 5.7 27.0 ± 2.0 29.1 ± 4.6
Total cholesterol (mmol/L) 183.6 ± 38.9 211.2 ± 41.7 174.9 ± 35.9
Triglyceride (mmol/L) (1) 83.25 ± 8.3 123.4 ± 0.3* 99.5 ± 53.0
HDL (mmol/L) 51.0 ± 21.4 43.2 ± 16.0 33.55 ± 9.1
LDL (mmol/L) 103.5 ± 34.7 137.1 ± 27.0 108.1 ± 35.3
Apo B100 (mg/dL) 103.8 ± 8.1 125.6 ± 7.1* 104.8 ± 9
Apo A1 (mg/dL) 151.6 ± 7.2 155.4 ± 7.2 143.7 ± 9
Castelli Index 3.93 ± 0.54 4.80 ± 0.53* 4.80 ± 0.31*
Apo B100/Apo A1 0.58 ± 0.16 0.85 ± 0.30* 0.70 ± 0.15*
Symptoms began by 1–2 months’ average after the time of the investigation. Control: 
healthy subjects.
*p < 0.05 vs. control.
CPs, cutaneous psoriasis group; PsA, psoriatic arthritis group; n, number of patients; 
BMI, body mass index.
4
Kolliker Frers et al. Inflammatory Cardiovascular Risk in Psoriasis
Frontiers in Immunology | www.frontiersin.org February 2018 | Volume 9 | Article 139
(BD Biosciences, San Jose, CA, USA). The detection limit was 
4.7pg/mL.
Tumor Necrosis Factor Alpha (TNF-α)
The human TNF-α ELISA kit (BD Biosciences, NJ, USA) was 
used to quantify TNF-α level. The detection limit was 7.8 pg/mL.
Monocyte Chemoattractant Protein-1 (MCP-1)
The concentration of MCP-1 was measured using the Human 
Quantikine MCP-1 ELISA. The detection limit was 2.31 pg/mL.
Soluble Intercellular Adhesion Molecule-1 (sICAM-1)
The Human Quantikine sICAM-1/CD54 ELISA kit was used to 
determine sICAM-1 levels in serum (R&D Systems, Minneapolis, 
USA). The detection limit was 1.56 ng/mL.
statistical analysis
Continuous variables were explored for normality and equality 
of variance (Levene’s test). Results were submitted to the analysis 
of variance (ANOVA) with Dunnett’s post hoc test for between-
group comparison and expressed as mean ± SD. Non-parametric 
data were analyzed using the Kruskal–Wallis test (for variance) 
and the Dunn’s test for multiple comparisons. A value of p < 0.05 
was considered statistically significant. Analyses were performed 
using Instat version 5.0 for Windows (GraphPad Software, La 
Jolla CA, USA). Plots show individual data instead of the typi-
cal mean and SD parameters used for large samples, due to the 
relatively small number of patients in our study.
resUlTs
Demographical Data and lipid 
Measurements
Following the selection process, 32 patients entered the study. 
Three groups were identified: C (9 control healthy patients, 8:1 
male-female ratio), CPs (9 low-intermediate CPs patients, 6:3 
male-female ratio), and PsA (14 patients with recent PsA onset, 
11:3 male-female ratio). The groups were not different according 
to age, BMI, gender and conventional cardiovascular risk factors 
(Table 1). Compared with control patients, the CPs group showed 
increase in TG (48%, p <  0.05) and ApoB100 (21%, p <  0.05) 
level, Castelli index (p < 0.05), and the ApoB100/Apo A1 ratio 
(p < 0.05) (Table 1). The PsA group showed higher Castelli index 
(p < 0.05) and ApoB100/Apo A1 ratio (p < 0.05) compared with 
control patients (Table 1).
inflammatory Biomarkers
The PsA group showed a dramatic increase in hs-CRP level com-
pared with both C (p < 0.01) and CPs (p < 0.05) groups (Figure 1A). 
Also, the level of sICAM1 increased by 54% (p < 0.05) in PsA 
compared with control patients. Other inflammatory biomark-
ers as IL-6 (Figure 1), TNF-α (2.2 ± 0.9 in C, 1.4 ± 0.7 in CPs, 
3.6 ± 2.1 in PsA) or MCP-1 (142.2 ± 7.6 in C, 160.5 ± 14.4 in CPs, 
142.3 ± 11.5 in PsA) did not change in any group. As expected, the 
erythrocyte sedimentation rate (ESR, mm/h) increased in both 
CPs (85.8 ± 9.1, p < 0.01) and PsA (53.0 ± 17.7, p < 0.01) groups 
compared with control patients (12.7 ± 5.1).
carotid intima–Media Thickness
Only PsA patients (0.590  ±  0.045), unlike CPs patients 
(0.621  ±  0.100), showed higher cIMT values compared with 
controls (0.436 ± 0.051) (Table 2; Figures 2 and 3).
Psoriasis area and severity index (Pasi)
CPs (5.857 ±  0.950) patients showed higher PASI values com-
pared with PsA (3.042 ± 0.951).
DiscUssiOn
In the past decade, the critical role of inflammation in the 
development of cardiovascular diseases has been accepted. 
Current evidence suggests that the inflammatory pathway in 
atherosclerosis culminates in altered concentrations of various 
markers in peripheral blood (31, 32) including CRP (44), IL-6, 
TNF-α, MCP-1, and ICAM1 (45–47). In 2013, the European Task 
Force for cardiovascular prevention and The American Heart 
Association and US Centers for Disease Control and Prevention 
(2013) recommended the use of only CRP among inflammatory 
biomarkers. Recently the Task Force established 24 inflammatory 
mediators including TNF, IL-6, sICAM-1, and MCP-1, presently 
accepted as potential surrogate biomarkers of CVR. Despite the 
supporting literature they have only a marginal use in clinical 
practice (17, 18).
inflammatory and Morphological 
subclinical Biomarkers in the context  
of systemic inflammatory Burden
CVR-Related Serologic Biomarkers
Our findings show an increase of nonconventional inflamma-
tory biomarkers of CVR in blood near the onset of symptoms 
and signs of PsA, even in the absence of conventional CVRFs. 
Psoriatic patients with no cardiovascular history or CVRFs 
showed an increase in CRP, sICAM-1 blood levels and cIMT 
compared with age- and BMI-matched control subjects. Of note, 
only selected PsA patients progressing from previous low or mild 
TaBle 2 | Inflammatory markers and characteristics of carotid artery wall.
Variable (mean ± sD) control (n = 9) cPs (n = 9) Psa (n = 14)
ESR (mm/h) 12.7 ± 5.1 85.8 ± 9.1** 53.0 ± 17.7**
sICAM-1 (ng/mL) 174.8 ± 11.9 221.2 ± 40.2 269.3 ± 2.4*
IL-6 (pg/mL) 16.3 ± 2.5 18 ± 2.9 23.3 ± 5.5
hs-CRP (mg/L) 3.15 ± 1.85 3.26 ± 0.76 8.4 ± 4.4**
TNF-α (pg/mL) 2.1 ± 1.0 1.4 ± 0.7 3.6 ± 2.1 
MCP-1 (pg/mL) 142.2 ± 7.6 160.5 ± 14.4 142.3 ± 11.5
Mean cIMT (mm) 0.436 ± 0.051 0.621 ± 0.100 0.590 ± 0.045*
Plaques (No./total) and (%) 0 (0); 0 3 (3/9); 33 1 (1/14); 7.14
Control: healthy subjects. Data are expressed as mean ± SD.
*p < 0.05 vs. control.
**p < 0.01 vs. control.
CPs, cutaneous psoriasis group; PsA, psoriatic arthritis group; n, number of patients; 
ESR, erythrocyte sedimentation rate (normal: ≤22 mm/h in men, ≤29 mm/h in women); 
cIMT, carotid intima–media thickness;IL-6, interleukin-6; sICAM-1, soluble intercellular 
adhesion molecule-1; hs-CRP, high-sensitivity C-reactive protein; cIMT, intima–media 
thickness.
FigUre 1 | Serum level of iinflammatory biomarkers. Individual data are plotted along with the typical mean and SD parameters due to the relatively small number 
of patients in this study. Control: healthy subjects. CPs, cutaneous psoriasis group; PsA, psoriatic arthritis group; n, number of patients. *p < 0.05, **p < 0.01 
between indicated groups. (a): hs-CRP, high-sensitivity C-reactive protein; (B): IL-6, interleukin-6; (c): sICAM-1, soluble intercellular adhesion molecule-1.
FigUre 2 | Carotid IMT. Individual data are plotted along with the typical 
mean and SD parameters due to the relatively small number of patients in 
this study. Control: healthy subjects. CPs, cutaneous psoriasis group; PsA, 
psoriatic arthritis group; n, number of patients. *p < 0.05 between indicated 
groups. IMT, intima–media thickness.
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CPs entered the study to assure homogeneity of the inflammatory 
context without medication.
These data agree with current epidemiologic evidence predict-
ing associated CVR (44), and the early role of these biomarkers in 
atherosclerosis. Our findings agree with the high level of sICAM-1 
and of other inflammatory biomarkers found in matched age and 
gender psoriatic patients (40). These findings may be interpreted 
as predictors of future arterial disease (23).
In population studies, serum levels of MCP-1 correlate 
with CVR factors and with coronary and peripheral artery 
FigUre 3 | Representative echocardiography images of control patients (left) and PsA patients (right). The left image shows a normal carotid wall with normal 
intima/media thickness (cIMT = 0.47 mm) in a control patient. Compared with the control image, the right image clearly shows carotid wall thickening 
(cIMT = 0.73 mm) in a PsA patient.
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disease incidence (24). The level of MCP-1 in the blood may be 
involved in the pathogenesis and activity of Psoriasis vulgaris 
(48). In our study, we did not observe changes in MCP-1 level in 
blood.
Results do not allow us to know if systemic concentrations of 
sICAM1 and MCP-1 derived exclusively from the endothelium 
or whether TNF-α and IL-6 derived only from immune cells. 
Different sources as the white adipose tissue, the liver and auto-
immune targets like skin and joints contribute to the systemic 
levels of MCP-1, sICAM1, IL-6, and TNF-α (16).
In turn, a sustained increase in the level of IL-6 and TNF-α 
favors the hepatic release of acute-phase reactants including 
CRPs (42), critically involved in PsA, CPs, and atherosclerosis. 
However, the increase in CRP might be related to increased level 
of cytokines other than IL-6 which did not show changes in pso-
riatic patients in our study. We have found an increase in IL-1β 
level in PsA patients compared with controls (21.60 ± 2.39 vs. 
14.64 ± 2.98, respectively, p < 0.05) that might account for CRP 
release. Additionally, in psoriatic patients, the skin releases 
IL-22 which might also help to explain the increased in CRP 
level in our study. The release of MCP-1, sICAM1, IL-6, and 
TNF-α is critically determinant in defining the load of systemic 
inflammation (16). Our results indicate an enhanced inflam-
matory burden reflected by carotid wall thickening and higher 
blood level of sICAM-1 and CRP in PsA patients without 
conventional risk factors. Pathological metabolic inflamma-
tory activated pathways seem to be necessary to fully release 
TNF-α and MCP-1 from adipose tissue, limiting blood levels of 
TNF-α and MCP-1. In our study, TNF-α and MCP-1 differences 
between psoriatic patients and controls did not reach statistical 
significance. Recent findings suggest that the nutrient-induced 
gut hormone gastric inhibitory polypeptide induces adipose tis-
sue inflammation by triggering a crosstalk between adipocytes 
and macrophages involving MCP-1 (47, 49, 50, 51). Elevation 
of ICAM-1 released by adipose tissue does not require TNF-
α to upregulate its expression. How excess body fat triggers 
inflammatory-like responses is not clear, but it is thought to 
involve elevated levels of cytokines (52), ICAM-1 (53, 54), and 
MCP-1 (50, 52).
Intima–Media Thickness
The increase of cIMT is a robust and early indicator of overall 
atherosclerosis (15). It has been used as a surrogate marker 
of subclinical atherosclerosis and considered a non-invasive 
diagnostic tool for identification of premature atheroscle-
rosis. Our study indicates an increase in cIMT suggesting a 
proatherogenic condition in psoriatic patients with higher 
systemic levels of inflammatory biomarkers and absence of 
conventional CVRFs.
Due to the exclusion criteria in this study, total systemic 
inflammation likely resulted from limited adipose tissue inflam-
mation or metabolic load and from low to mild inflammation 
of the skin and joints according to PASI and DAS28 score or 
autoimmune load. In previous studies, patients developed 
hypertriglyceridemia and showed an increase in the ApoB100/
ApoA1 ratio, both atherogenic and increasing cardiovascular 
risk (55). Others have also reported changes in HDL levels (56). 
Present findings agree with the positive association reported for 
the ApoB/ApoA-I ratio with cIMT, suggested as a suitable tool for 
early detection of premature atherosclerosis in psoriasis patients 
(17, 18). One study reported a higher prevalence of triglycerides 
and lower prevalence of low HDL levels in Ps patients (56).
Integrative interpretation of a subset of measures, e.g., cIMT, 
CRP, and sICAM-1, and calculation of the ApoB100/ApoA1 ratio 
might help in the early estimation of premature atherosclerosis in 
psoriatic patients. Carotid wall thickening is related to conven-
tional CVRFs like age, BMI, and the level of TG, LDL-cholesterol, 
and total cholesterol in blood (11, 57).
The presence of carotid plaques correlated with hypertriglyc-
eridemia and psoriasis activity (PASI and DAS28 values) (58). 
Qu et al. reported that cIMT increases with the load of classical 
risk factors and with the level of CRP (59).
Notwithstanding the exclusion of hypertriglyceridemia in the 
selection process prestudy, CPs patients showed higher TG level 
compared with either control of PsA patients.
To date, CRP appears to be the only inflammatory marker 
used as a potential predictor of overall atherosclerosis. Even so, 
measuring CRP level is still discussed in the general population 
and even in the context of IMID.
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In this study, the level of some biomarkers of proatherogenesis 
did not follow the patients’ clinical status what may seem at first 
counterintuitive. Although the level of sICAM-1, IL-6, hs-CRP, 
and TNF-α appeared to be higher in PsA than in CPs patients, 
ESR, MCP-1, and probably also cIMT apparently developed in 
the opposite direction as CPs patients showed higher values com-
pared with PsA patients. One possible explanation is that ESR, 
MCP-1, and cIMT might be more sensitive to the activity of the 
disease as evidenced by PASI values. Then, a large skin damage 
(a higher PASI index) might be crucial in raising the value of the 
ESR, and the level of MCP-1 and cIMT in CPs patients. Also, the 
level of ESR, MCP-1, and cIMT might be more sensitive to tradi-
tional CV risk lipid factors. Within normal values, the CPs group 
showed higher level of total cholesterol, TG, and LDL-cholesterol 
than the PsA group.
atherosclerosis Tendency
In sum, patients with recent-onset PsA showed an increase in 
cIMT and blood level of sICAM-1 and CRP compared with 
healthy controls in our study. In low-mild CPs patients, CRP and 
sICAM-1 levels were not different from those found in healthy 
controls. The level of IL-6 showed a mild increasing trend with the 
severity and clinical expression of the disease, though between-
group differences were not statistically significant. Likewise, the 
groups were indistinguishable based on the level of MCP-1 and 
TNF-α.
Psoriasis target tissues like skin and joints critically con-
tribute to systemic inflammation. The strict exclusion criteria 
limited the conventional cardiovascular risk factors which 
nevertheless likely contributed to the overall inflammatory 
burden.
It is time to obtain a new built-in CVR index considering both 
compartments. The IMIDs may need special consideration due to 
the intrinsic and chronic autoimmune inflammation. Certainly, 
both conventional and non-conventional CVRFs contribute to 
systemic inflammation and interact with each other inducing the 
final systemic load of inflammation (16).
cOnclUsiOn
Our results suggest that recently diagnosed non-medicated 
PsA patients without conventional CV risk factors develop 
subtle chronic inflammatory changes as the observed increase 
in sICAM1, and CRP which might foster microenvironmental 
conditions for carotid wall thickening.
Recent onset PsA patients no medicated develop sub-
clinical atherosclerosis compared with controls compared with 
patients with low-mild (no medicated) CPs. The degree of 
atherosclerosis tendency may be related to the amount of the 
inflammatory burden suggesting an ongoing subclinical inflam-
mation either previous or concurrent with joints’ damage. The 
release of autoimmune inflammatory mediators may account 
for the increase in systemic inflammatory burden in PsA and 
CPs patients with low disease activity in our study. However, 
the amount of metabolic load contributes to fully expressing 
proatherogenic inflammation.
Psoriatic patients are known to have a high level of TG and low 
level of HDL even within normal values compared with healthy 
subjects as observed in our study. The ApoB100/ApoAI ratio and 
Castelli index reflect the counterbalance between proatherogenic 
and antiatherogenic lipoproteins (39) related to CVR. The former 
seems to be a better predictor of cardiovascular disease than the 
latter (60).
The strict exclusion criteria for conventional CVRFs resulted 
in a long time of recruitment and a relatively small number of 
subjects. We encourage further research including a larger num-
ber of patients to confirm present information.
study limitations
Sample size is very small. Recruiting patients complying with 
the inclusion and exclusion criteria required for our study took 
us several years. One major handicap limiting the sample size 
was the essential requirement on the absence of traditional car-
diovascular risk factors in patients around their fifties. Also, the 
seemingly counterintuitive mismatch between the level of some 
biomarkers of proatherogenesis and the patients’ clinical status 
deserves further review.
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